drugset / Trial / NCT06449352

Effect of Netarsudil vs Brimonidine in NTG Patients on Latanoprost

NCT06449352

Phase 4 Completed 100 enrolled Westlake Eye Specialists Sengi · collab
RandomizedParallel-groupDouble-blindBasic science

Summary

A randomized, multicenter, investigator-masked prospective study of NTG patients currently on latanoprost 0.005% monotherapy, to study the effect of IOP change with the introduction of netarsudil 0.02% vs brimonidine 0.1%. Subjects will be assessed at a screening visit, and 1 follow-up visit. Clinical evaluations will include visual acuity and IOP .

Timeline

Start
2024-06-13
Primary completion
2025-09-22
Completion
2025-09-22

Drugs

EvaluationDrugModalityDoseRoute
Comparator Brimonidine Small molecule 0.1 %
Subject Netarsudil Small molecule 0.02 %

Indications